Morgan Stanley Sees St. Jude Medical as Poised for Acceleration

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $75.00 price target on St. Jude Medical STJ. In the report, Morgan Stanley noted, “End market stability and pipeline catalysts into 2H14 suggest acceleration across the next several quarters and upside to management's 3-5% outlook. Revenue sustainability and leverage into 2015 support increasing visibility on our $75 target.” St. Jude Medical closed on Friday at $62.00.